Karuna Therapeutics, Inc. (KRTX) News

Karuna Therapeutics, Inc. (KRTX): $126.10

-0.41 (-0.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter KRTX News Items

KRTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

KRTX News Highlights

  • For KRTX, its 30 day story count is now at 6.
  • Over the past 23 days, the trend for KRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • DECK and ORIC are the most mentioned tickers in articles about KRTX.

Latest KRTX News From Around the Web

Below are the latest news stories about Karuna Therapeutics Inc that investors may wish to consider to help them evaluate KRTX as an investment opportunity.

Karuna Therapeutics (KRTX) Presents At Annual SVB Leerink Global Health Conference

The following slide deck was published by Karuna Therapeutics, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | February 24, 2022

Karuna Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides General Business Update

BOSTON, February 24, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided a general business update.

Yahoo | February 24, 2022

Karuna Therapeutics' Schizophrenia Drug Could Be a Blockbuster

Analysts say company is taking novel approach to treating mental illnesses, Alzheimer's

Yahoo | February 22, 2022

One Karuna Therapeutics, Inc. (NASDAQ:KRTX) insider upped their stake by 2.2% in the previous year

Viewing insider transactions for Karuna Therapeutics, Inc.'s ( NASDAQ:KRTX ) over the last year, we see that insiders...

Yahoo | February 16, 2022

Emerald Mutual Fund Advisers Trust Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA ...

Leola, PA, based Investment company Emerald Mutual Fund Advisers Trust (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, Karuna Therapeutics Inc, HireRight Holdings Corp, sells Chegg Inc, BellRing Brands Inc, Echo Global Logistics Inc, Tetra Tech Inc, ORIC Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Mutual Fund Advisers Trust.

Yahoo | February 2, 2022

Karuna Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

BOSTON, February 01, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will participate in the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 10:00 a.m. ET.

Yahoo | February 1, 2022

Karuna Therapeutics: Starting A Position With 50% Short-Term Upside Potential

No summary available.

Seeking Alpha | January 14, 2022

Karuna Therapeutics (KRTX) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

No summary available.

Seeking Alpha | January 12, 2022

3 Can't-Miss Biotech Events Coming Up in 2022

Here's why you'll want to keep both eyes open for upcoming announcements from Alnylam Pharmaceuticals (NASDAQ: ALNY), Intercept Pharmaceuticals (NASDAQ: ICPT), and Karuna Therapeutics (NASDAQ: KRTX). Shares of Alnylam recently slipped around 15% overnight in response to a surprising clinical-trial flop for a drug it isn't even developing. Recently, BridgeBio Pharma told investors that people with heart damage caused by transthyretin amyloidosis (ATTR) who received acoramidis failed to outperform the placebo group on the six-minute walking test.

Yahoo | January 7, 2022

Karuna Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON, January 04, 2022--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairman, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 a.m. ET.

Yahoo | January 4, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4707 seconds.